Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Challenging Anticoagulant Therapy in Patient with COVID-19-Associated Coagulopathy

ACTA MEDICA INDONESIANA · Vol. 53 No. 3 (2021)

ISSN
2338-2732, 0125-9326
Terbit
2021-10-04
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

COVID-19 became a widespread infectious disease in late 2019. Indonesia currently has the highest COVID-19 mortality rate in Asia, between 4-5 percent. Interestingly, COVID-19-associated coagulopathy characterized by an increase of several procoagulant factor levels, including fibrinogen and D-dimer, that has been associated with higher mortality and unfavorable outcomes. We report a case of a 30-year-old male admitted to the hospital with a profuse vomiting and worsening fever, cough and shortness of breath, and was diagnosed with COVID-19-associated coagulopathy. Seven days after admission, he became deteriorated with significant reduction of oxygen saturation and his coagulation parameter levels were increased with highly suspicion of pulmonary embolism. He was treated with azithromycin, isoprinosine, lopinavir, and fondaparinux with thromboprophylaxis dosage since admission. The role of increased fondaparinux dosage at the time of clinical deterioration was then followed by clinical improvement and reduced D-dimer level. Anticoagulant therapy, mainly with fondaparinux, showed a better prognosis in patients with markedly elevated D-Dimer. Fondaparinux needs to be monitored appropriately to prevent bleeding and adverse. The patient was discharged from the hospital in an improved condition and normal D-Dimer levels. There were no bleeding event nor other major side effects that had been found. The decision for increasing dose of anticoagulant may be determined on individual basis, considering risks, benefits, and also the most important is clinical findings.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 274 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Ummi MaimunahAfiliasi tidak diketahui3
Ulfa KholiliAfiliasi tidak diketahui3
Titong SugihartonoAfiliasi tidak diketahui3
Yudith Annisa Ayu RezkithaAfiliasi tidak diketahui2
Yoshio YamaokaAfiliasi tidak diketahui2
Herry PurbayuAfiliasi tidak diketahui2
Iswan Abbas NusiAfiliasi tidak diketahui2
Budi WidodoAfiliasi tidak diketahui2
Amie VidyaniAfiliasi tidak diketahui2
Husin ThamrinAfiliasi tidak diketahui2
Iswan A NusiAfiliasi tidak diketahui1
Pangestu AdiAfiliasi tidak diketahui1
Dadang MakmunAfiliasi tidak diketahui1
Manu TandanAfiliasi tidak diketahui1
Nitin JagtapAfiliasi tidak diketahui1
Pintu BhakharAfiliasi tidak diketahui1
Yashavanth H SAfiliasi tidak diketahui1
Pankaj ShrimalAfiliasi tidak diketahui1
Mithun SharmaAfiliasi tidak diketahui1
Rajesh GuptaAfiliasi tidak diketahui1
P N RaoAfiliasi tidak diketahui1
D Nageshwar ReddyAfiliasi tidak diketahui1
Ari Fahrial SyamAfiliasi tidak diketahui1
Chyntia Dewi Maharani PutriAfiliasi tidak diketahui1
Diah PriyantiniAfiliasi tidak diketahui1
Hartono KaharAfiliasi tidak diketahui1
Poernomo Boedi SetiawanAfiliasi tidak diketahui1
Langgeng Agung WaskitoAfiliasi tidak diketahui1
Gontar Alamsyah SiregarAfiliasi tidak diketahui1
Reny I’tishomAfiliasi tidak diketahui1
Tomohisa UchidaAfiliasi tidak diketahui1
Poernomo B SetiawanAfiliasi tidak diketahui1
Annisa Zahra MufidaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Challenging Anticoagulant Therapy in Patient with COVID-19-Associated Coagulopathy</dc:title>
	<dc:creator>Rianda, Raissa Virgy</dc:creator>
	<dc:creator>Subkhan, Mohammad</dc:creator>
	<dc:creator>Pradana, Aditya Doni</dc:creator>
	<dc:creator>Fatimah, Fahrun Nisa’i</dc:creator>
	<dc:creator>Rianda, Rama Azalix</dc:creator>
	<dc:creator>Airlangga, Muhammad Perdana</dc:creator>
	<dc:creator>Miftahussurur, Muhammad</dc:creator>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">Coagulopathy</dc:subject>
	<dc:subject xml:lang="en-US">Fondaparinux</dc:subject>
	<dc:subject xml:lang="en-US">Anticoagulation</dc:subject>
	<dc:subject xml:lang="en-US">Thrombosis</dc:subject>
	<dc:subject xml:lang="en-US">hematology</dc:subject>
	<dc:subject xml:lang="en-US">infection</dc:subject>
	<dc:subject xml:lang="en-US">pulmonology</dc:subject>
	<dc:description xml:lang="en-US">COVID-19 became a widespread infectious disease in late 2019. Indonesia currently has the highest COVID-19 mortality rate in Asia, between 4-5 percent. Interestingly, COVID-19-associated coagulopathy characterized by an increase of several procoagulant factor levels, including fibrinogen and D-dimer, that has been associated with higher mortality and unfavorable outcomes. We report a case of a 30-year-old male admitted to the hospital with a profuse vomiting and worsening fever, cough and shortness of breath, and was diagnosed with COVID-19-associated coagulopathy. Seven days after admission, he became deteriorated with significant reduction of oxygen saturation and his coagulation parameter levels were increased with highly suspicion of pulmonary embolism. He was treated with azithromycin, isoprinosine, lopinavir, and fondaparinux with thromboprophylaxis dosage since admission. The role of increased fondaparinux dosage at the time of clinical deterioration was then followed by clinical improvement and reduced D-dimer level. Anticoagulant therapy, mainly with fondaparinux, showed a better prognosis in patients with markedly elevated D-Dimer. Fondaparinux needs to be monitored appropriately to prevent bleeding and adverse. The patient was discharged from the hospital in an improved condition and normal D-Dimer levels. There were no bleeding event nor other major side effects that had been found. The decision for increasing dose of anticoagulant may be determined on individual basis, considering risks, benefits, and also the most important is clinical findings.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2021-10-04</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1606</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 53 No. 3 (2021): Acta Medica Indonesiana; 308</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1606/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2021 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>